glp 1 injection site red and itchy Delayed type hypersensitivity reaction tolerance induction to liraglutide for the treatment of obesity Injection site reactions can present

Your consultation includes a clinical review, body composition assessment, and a personalized plan based on your health history, metabolism, and goals

We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )

Many patients starting GLP-1 therapy wonder about safety margins and what constitutes dangerous dosing

Additionally, optimal treatment of DGp includes good glycemic management, often involving customizing insulin delivery using basal-bolus insulin and technology, including sensor-augmented pumps and continuous glucose monitoring systems